ArticleBMC gastroenterology2025
Evaluation of the direct cost of chronic viral hepatitis B in patients monitored at the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic viral hepatitis B constitutes a public health problem due to its morbidity, mortality and economic consequences. To date, the direct costs incurred by patients for the treatment of this condition are not well documented. Our study aims to provide evidence on this cost in order to help facilitate patient care and optimize national hepatitis control policies. METHODOLOGY: This is a cross-sectional study with analytical aims lasting one month. The study population consisted of patients followed in outpatient consultation in the hepato-gastroenterology department of the Yalgado OUEDRAOGO University Hospital Center (CHU-YO). We conducted a census of patients seen in consultation and meeting the inclusion criteria. Data were collected following direct interviews with patients and review of medical records. The determinants of the direct cost of chronic viral hepatitis B management were identified using linear regression.
resultsThe mean direct cost incurred by patients on tenofovir treatment during the first three years of follow-up was 538,293 XOF with a 95% CI [466,005-610,581] and a standard deviation of 35,739 XOF. The mean direct cost incurred by patients without tenofovir treatment during the first three years of follow-up was 359,664 XOF (≈ 611.4 USD) with a 95% CI [331,276-388,052] XOF and a standard deviation of 14,323 XOF . The mean non-medical direct cost during the first three years of follow-up was 30,037 XOF (≈ 52.14 USD) with a 95% CI [22,498-37,575] XOF and a standard deviation of 3,815 XOF.
conclusionThe cost of chronic viral hepatitis B treatment at CHU-YO is very high compared to patients' income. Laboratory and imaging tests constitute the bulk of patient care expenses. To facilitate patient monitoring in order to avoid or delay the occurrence of complications, it is necessary to implement financial protection mechanisms in health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.